GlassScriptPhysician profile
Richard Mayse
NPI 1487735999
$1,088.47
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $335.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $105.82 | 2019 | |
| Grifols USA, LLC | $87.28 | 2019 | |
| Csl Behring | $86.59 | 2019 | |
| Genentech USA, INC. | $62.87 | 2019 | |
| Shire North American Group INC | $57.42 | 2019 | |
| Octapharma USA, INC. | $57.38 | 2019 | |
| Mylan Specialty L.P. | $45.65 | 2019 | |
| Covis Pharma Gmbh | $41.55 | 2019 | |
| Alk-Abello, INC | $37.16 | 2019 | |
| Neos Therapeutics, LP | $20.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.40 | 2019 | |
| Pfizer INC. | $12.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mayse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.